The editorial discusses the ongoing outbreak of Coronavirus Disease 2019 (Covid-19), which was first recognized in December 2019. It is a novel coronavirus related to SARS and MERS, posing significant challenges for public health, research, and medicine. A study by Li et al. describes the first 425 cases in Wuhan, China, noting a median age of 59, higher morbidity and mortality in the elderly and those with coexisting conditions, and no cases in children under 15. The case fatality rate is estimated at around 2%, though this may be lower if asymptomatic cases are considered. The basic reproduction number (R0) is estimated at 2.2, indicating the virus spreads to two people per infected individual. Travel restrictions have been implemented to slow the spread, but community transmission could lead to a shift from containment to mitigation strategies like social distancing. Research is ongoing to develop a vaccine, with phase 1 trials expected by early spring. Therapies under investigation include antivirals, interferons, and monoclonal antibodies. The outbreak highlights the need for continuous surveillance, prompt diagnosis, and robust research to understand the virus and develop countermeasures. The study also notes a delay in progression to severe disease, offering a window for intervention. Genomic studies may help identify factors predisposing individuals to infection. The outbreak underscores the ongoing challenge of emerging infectious diseases and the importance of global cooperation in responding to such threats.The editorial discusses the ongoing outbreak of Coronavirus Disease 2019 (Covid-19), which was first recognized in December 2019. It is a novel coronavirus related to SARS and MERS, posing significant challenges for public health, research, and medicine. A study by Li et al. describes the first 425 cases in Wuhan, China, noting a median age of 59, higher morbidity and mortality in the elderly and those with coexisting conditions, and no cases in children under 15. The case fatality rate is estimated at around 2%, though this may be lower if asymptomatic cases are considered. The basic reproduction number (R0) is estimated at 2.2, indicating the virus spreads to two people per infected individual. Travel restrictions have been implemented to slow the spread, but community transmission could lead to a shift from containment to mitigation strategies like social distancing. Research is ongoing to develop a vaccine, with phase 1 trials expected by early spring. Therapies under investigation include antivirals, interferons, and monoclonal antibodies. The outbreak highlights the need for continuous surveillance, prompt diagnosis, and robust research to understand the virus and develop countermeasures. The study also notes a delay in progression to severe disease, offering a window for intervention. Genomic studies may help identify factors predisposing individuals to infection. The outbreak underscores the ongoing challenge of emerging infectious diseases and the importance of global cooperation in responding to such threats.